利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.023 秒)

    Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates
    1.
    发明授权
    Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates 失效
    使用B1，B3或B5靶向免疫缀合物抑制携带LewisY抗原的细胞生长的方法

    公开(公告)号：US06287562B1

    公开(公告)日：2001-09-11

    申请号：US09227693

    申请日：1999-01-08

    申请人： Ira Pastan ,  Itai Benhar ,  Eduardo A. Padlan ,  Sun-Hee Jung ,  Byungkook Lee

    发明人： Ira Pastan ,  Itai Benhar ,  Eduardo A. Padlan ,  Sun-Hee Jung ,  Byungkook Lee

    IPC分类号： A61K39395

    CPC分类号： G01N33/57419 ,  A61K38/00 ,  A61K47/6851 ,  C07K14/21 ,  C07K16/18 ,  C07K16/30 ,  C07K16/34 ,  C07K19/00 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  G01N33/57446 ,  G01N33/57449 ,  G01N33/57492

    摘要： The invention provides methods for inhibiting the growth of a cell bearing a LewisY antigen. The methods involve contacting the cell with a composition comprising an Fv region of a light chain of a monoclonal antibody selected from B1, B3, and B5, and the Fv region of a humanized heavy chain of a monoclonal antibody independently selected from B1, B3, and B5, provided that if the heavy and the light chains are from the same antibody, the residue at position 95 of the heavy chain is a serine, and, if the antibody chain is from B3, the residue at position 4 of the light chain can be a leucine and the residue at position 82b of the heavy chain can be an arginine. The Fv regions are joined to an effector molecule selected from a chemotherapeutic agent, a toxin, a radioisotope, and a liposome loaded with a chemotherapeutic agent. In preferred embodiments, the heavy chain and the light chain are recombinantly fused, and the Fv regions are recombinantly fused to a toxin.

    摘要翻译： 本发明提供了抑制携带LewisY抗原的细胞生长的方法。 所述方法包括使细胞与包含选自B1，B3和B5的单克隆抗体的轻链的Fv区和单独抗体的人源化重链的Fv区的组合物接触，所述单克隆抗体独立地选自B1，B3， 和B5，条件是如果重链和轻链来自相同的抗体，则重链位置95处的残基是丝氨酸，并且如果抗体链来自B3，则轻链第4位的残基 可以是亮氨酸，重链位置82b处的残基可以是精氨酸。 Fv区连接到选自化疗剂，毒素，放射性同位素和装载有化学治疗剂的脂质体的效应分子。 在优选的实施方案中，将重链和轻链重组融合，并将Fv区重组融合至毒素。